A Red Cross volunteer counts tablets for an HIV-positive patient in Kenya. (Photo: International Federation of the Red Cross and Red Crescent Societies/flickr/cc)
Dec 01, 2015
The Trans-Pacific Partnership (TPP), a controversial 12-nation deal that critics warn favors corporate power over public health, specifically threatens access to essential drugs for people with HIV and AIDS, an advocacy group warned Tuesday marking World AIDS Day.
"By harming access to live-saving medications, the TPP poses a real threat to our continued progress in fighting the pandemic," said Jerame Davis, executive director of Pride at Work, an AFL-CIO subsidiary that organizes support for labor and LGBTQI issues. "Continued worldwide progress in containing and fighting back against HIV/AIDS means access to affordable drugs."
Provisions in the TPP would allow, among other things, extended patents on biologics that would grant Big Pharma free rein to ratchet up prices on what Pride at Work calls "the most effective" HIV/AIDS medications.
As economist Dean Baker recently explained, "Patent monopolies provide both enormous incentive and opportunity for drug companies to increase profits at the expense of patients."
Such monopolistic protections for drug manufacturers--which already exist to some extent and would only be expanded through the so-called trade deal--"would have a dramatic effect on access to safe and affordable care for millions of people worldwide," Pride at Work said Tuesday.
International aid agency Oxfam in May warned that the TPP would "do more to undermine access to affordable medicines than any previous U.S. trade agreement" and that the agreement's intellectual property provisions "are incoherent and inconsistent with U.S. global health policy."
In one example, Oxfam found that under the TPP's rules, more than half of HIV/AIDS patients in Vietnam would lose access to vital medication. There are over 250,000 people living with those viruses in Vietnam alone.
"World AIDS Day is an annual chance to reflect on our battle against the HIV/AIDS pandemic and a reminder that we have an obligation to care for each other," Davis said Tuesday. "Treatment of those living with the virus is needed not only to save the lives those living with HIV/AIDS, but to prevent new infections as well--those who have access to treatment are less likely to pass on the virus. Our trade deals should put people before profits, but TPP would do just the opposite."
Join Us: News for people demanding a better world
Common Dreams is powered by optimists who believe in the power of informed and engaged citizens to ignite and enact change to make the world a better place. We're hundreds of thousands strong, but every single supporter makes the difference. Your contribution supports this bold media model—free, independent, and dedicated to reporting the facts every day. Stand with us in the fight for economic equality, social justice, human rights, and a more sustainable future. As a people-powered nonprofit news outlet, we cover the issues the corporate media never will. |
Our work is licensed under Creative Commons (CC BY-NC-ND 3.0). Feel free to republish and share widely.
Nadia Prupis
Nadia Prupis is a former Common Dreams staff writer. She wrote on media policy for Truthout.org and has been published in New America Media and AlterNet. She graduated from UC Santa Barbara with a BA in English in 2008.
The Trans-Pacific Partnership (TPP), a controversial 12-nation deal that critics warn favors corporate power over public health, specifically threatens access to essential drugs for people with HIV and AIDS, an advocacy group warned Tuesday marking World AIDS Day.
"By harming access to live-saving medications, the TPP poses a real threat to our continued progress in fighting the pandemic," said Jerame Davis, executive director of Pride at Work, an AFL-CIO subsidiary that organizes support for labor and LGBTQI issues. "Continued worldwide progress in containing and fighting back against HIV/AIDS means access to affordable drugs."
Provisions in the TPP would allow, among other things, extended patents on biologics that would grant Big Pharma free rein to ratchet up prices on what Pride at Work calls "the most effective" HIV/AIDS medications.
As economist Dean Baker recently explained, "Patent monopolies provide both enormous incentive and opportunity for drug companies to increase profits at the expense of patients."
Such monopolistic protections for drug manufacturers--which already exist to some extent and would only be expanded through the so-called trade deal--"would have a dramatic effect on access to safe and affordable care for millions of people worldwide," Pride at Work said Tuesday.
International aid agency Oxfam in May warned that the TPP would "do more to undermine access to affordable medicines than any previous U.S. trade agreement" and that the agreement's intellectual property provisions "are incoherent and inconsistent with U.S. global health policy."
In one example, Oxfam found that under the TPP's rules, more than half of HIV/AIDS patients in Vietnam would lose access to vital medication. There are over 250,000 people living with those viruses in Vietnam alone.
"World AIDS Day is an annual chance to reflect on our battle against the HIV/AIDS pandemic and a reminder that we have an obligation to care for each other," Davis said Tuesday. "Treatment of those living with the virus is needed not only to save the lives those living with HIV/AIDS, but to prevent new infections as well--those who have access to treatment are less likely to pass on the virus. Our trade deals should put people before profits, but TPP would do just the opposite."
Nadia Prupis
Nadia Prupis is a former Common Dreams staff writer. She wrote on media policy for Truthout.org and has been published in New America Media and AlterNet. She graduated from UC Santa Barbara with a BA in English in 2008.
The Trans-Pacific Partnership (TPP), a controversial 12-nation deal that critics warn favors corporate power over public health, specifically threatens access to essential drugs for people with HIV and AIDS, an advocacy group warned Tuesday marking World AIDS Day.
"By harming access to live-saving medications, the TPP poses a real threat to our continued progress in fighting the pandemic," said Jerame Davis, executive director of Pride at Work, an AFL-CIO subsidiary that organizes support for labor and LGBTQI issues. "Continued worldwide progress in containing and fighting back against HIV/AIDS means access to affordable drugs."
Provisions in the TPP would allow, among other things, extended patents on biologics that would grant Big Pharma free rein to ratchet up prices on what Pride at Work calls "the most effective" HIV/AIDS medications.
As economist Dean Baker recently explained, "Patent monopolies provide both enormous incentive and opportunity for drug companies to increase profits at the expense of patients."
Such monopolistic protections for drug manufacturers--which already exist to some extent and would only be expanded through the so-called trade deal--"would have a dramatic effect on access to safe and affordable care for millions of people worldwide," Pride at Work said Tuesday.
International aid agency Oxfam in May warned that the TPP would "do more to undermine access to affordable medicines than any previous U.S. trade agreement" and that the agreement's intellectual property provisions "are incoherent and inconsistent with U.S. global health policy."
In one example, Oxfam found that under the TPP's rules, more than half of HIV/AIDS patients in Vietnam would lose access to vital medication. There are over 250,000 people living with those viruses in Vietnam alone.
"World AIDS Day is an annual chance to reflect on our battle against the HIV/AIDS pandemic and a reminder that we have an obligation to care for each other," Davis said Tuesday. "Treatment of those living with the virus is needed not only to save the lives those living with HIV/AIDS, but to prevent new infections as well--those who have access to treatment are less likely to pass on the virus. Our trade deals should put people before profits, but TPP would do just the opposite."
We've had enough. The 1% own and operate the corporate media. They are doing everything they can to defend the status quo, squash dissent and protect the wealthy and the powerful. The Common Dreams media model is different. We cover the news that matters to the 99%. Our mission? To inform. To inspire. To ignite change for the common good. How? Nonprofit. Independent. Reader-supported. Free to read. Free to republish. Free to share. With no advertising. No paywalls. No selling of your data. Thousands of small donations fund our newsroom and allow us to continue publishing. Can you chip in? We can't do it without you. Thank you.